Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 20/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179857 | 0.92 | IMPDH2 (0.61) | IMPDH2 | |
| SCHEMBL6182668 | 0.91 | IMPDH2 (0.60) | IMPDH2 | |
| SCHEMBL5012543 | 0.88 | IMPDH2 (0.86) | IMPDH2 | |
| SCHEMBL6179758 | 0.87 | IMPDH2 (0.51) | IMPDH2 | |
| SCHEMBL6180740 | 0.86 | IMPDH2 (0.52) | IMPDH2 | |
| SCHEMBL1473908 | 0.83 | IMPDH2 (0.73) | IMPDH2 | |
| SCHEMBL6179213 | 0.82 | VCP (0.49) | IMPDH2 | |
| SCHEMBL1475417 | 0.82 | IMPDH2 (1.00) | IMPDH2 | |
| SCHEMBL1473135 | 0.82 | IMPDH2 (1.00) | IMPDH2 | |
| SCHEMBL1474502 | 0.82 | IMPDH2 (1.00) | IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1532103-A4 | USE OF COMPOUNDS HAVING AN AMINE NUCLEUS IN MANUFACTURE OF A MEDICAMENT USEFUL FOR TREATING FACTOR VIIA-ASSOCIATED CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20060173057-A1 | Methods of treating factor VIIa-associated conditions with compounds having an amine nucleus | HERPIN TIMOTHY | 2006-08-03 | — | — | US | disclosed |
| US-7041692-B2 | Methods of treating factor VIIa-associated conditions with compounds having an amine nucleus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1532103-A2 | USE OF COMPOUNDS HAVING AN AMINE NUCLEUS IN MANUFACTURE OF A MEDICAMENT USEFUL FOR TREATING FACTOR VIIA-ASSOCIATED CONDITIONS | Bristol-Myers Squibb Company (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040029940-A1 | Methods of treating factor VIIa-associated conditions with compounds having an amine nucleus | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-12 | — | — | US | disclosed |
| WO-2004000214-A2 | USE OF COMPOUNDS HAVING AN AMINE NUCLEUS IN MANUFACTURE OF A MEDICAMENT USEFUL FOR TREATING FACTOR VIIA-ASSOCIATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173057-A1 | Methods of treating factor VIIa-associated conditions with compounds having an amine nucleus | F7, F8, F13B | IMPDH2 2015/4885 |
| US-20040029940-A1 | Methods of treating factor VIIa-associated conditions with compounds having an amine nucleus | F7, F8, F13B | IMPDH2 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.